Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

Journal of the National Cancer Institute

Volumn 101, Issue 24, 2009, Pages 1735-1736

  Oakman, Catherine ^a   Moretti, Erica ^a   Sotiriou, Christos ^b   Viale, Giuseppe ^b   Di Leo, Angelo ^a,c  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING);

BREAST CANCER; CANCER ADJUVANT THERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; LETTER; ONCOGENE NEU; PRIORITY JOURNAL; TOP2A GENE;

EID: 72649099933     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp402     Document Type: Letter

References (6)

1. O'Malley F. Chia S. Tu D. et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009; 101(3):644-650.
2. Mueller RE. Parkes RK. Andrulis I. O'Malley FP. Amplifi cation of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer. 2004; 39(3):288-297.
3. Durbecq V. Desmedt C. Paesmans M. et al. Correlation between topoisomerase-II alpha gene amplifi cation and protein expression in HER-2 amplifi ed breast cancer. Int J Oncol. 2004; 25(3):1473-1479.
4. Mo YY. Beck WT. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines. Oncol Res. 1997; 9(3):193-204.
5. Treszezamsky AD. Kachnic LA. Feng Z. et al. BRCA1-and BRCA2-defi cient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res. 2007; 67(35):7078-7081.
6. Liedtke C. Mazouni C. Hess KR. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(3):1275-1281